Japanese Encephalitis – Pipeline Review, H2 2011

Japanese Encephalitis – Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Japanese Encephalitis - Pipeline Review, H2 2011', provides an overview of the Japanese Encephalitis therapeutic pipeline. This report provides information on the therapeutic development for Japanese Encephalitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Japanese Encephalitis. 'Japanese Encephalitis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Japanese Encephalitis.
• A review of the Japanese Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Japanese Encephalitis pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Japanese Encephalitis.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Japanese Encephalitis pipeline depth and focus of Japanese Encephalitis therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Japanese Encephalitis Overview
Therapeutics Development
An Overview of Pipeline Products for Japanese Encephalitis
Japanese Encephalitis Therapeutics under Development by Companies
Japanese Encephalitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Japanese Encephalitis Therapeutics – Products under Development by Companies
Japanese Encephalitis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Japanese Encephalitis Therapeutics Development
Sanofi-Aventis
Boryung Pharmaceutical Co., Ltd.
Panacea Biotec Limited
Sinovac Biotech Ltd.
Japanese Encephalitis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Japanese Encephalitis Inactivated Vaccine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
20% Diethyltoluamide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Japanese Encephalitis SA 14-14-2 Vaccine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Imojev - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Imojev - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Japanese Encephalitis Chimeric Virus Vaccine + MMR II Vaccine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Vero Cell-derived Inactivated Japanese Encephalitis Vaccine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
JEVAC - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Vero Cell Based Japanese Encephalitis Vaccine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Japanese Encephalitis Therapeutics – Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Japanese Encephalitis, H2 2011
Products under Development for Japanese Encephalitis – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Sanofi-Aventis, H2 2011
Boryung Pharmaceutical Co., Ltd., H2 2011
Panacea Biotec Limited, H2 2011
Sinovac Biotech Ltd., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Japanese Encephalitis Therapeutics – Drug Profile Updates

LIST OF FIGURES

Number of Products under Development for Japanese Encephalitis, H2 2011
Products under Development for Japanese Encephalitis – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011 Skip to top